No. The US has stronger biotech tools than in 2019 but remains inadequately prepared due to persistent supply-chain fragility, eroded institutional trust, bureaucratic dysfunction, healthcare capacity limits, and failure to fully correct COVID-era errors.
Concrete Strengths
•Platforms and speed: mRNA and related technologies (plus Operation Warp Speed-style acceleration) allow faster vaccine/therapeutic candidates against novel pathogens than traditional methods. Genomic sequencing, wastewater surveillance, and some antiviral stockpiles are better than pre-2020. BARDA, Project NextGen, and private-sector capacity (Moderna, Pfizer, smaller biotechs) provide real optionality.
•Resources and federalism: The US can surge money, the Defense Production Act, and National Guard support. States retain flexibility that pure central systems lack. Excess hospital capacity can be created temporarily; the Strategic National Stockpile has been partially rebuilt for PPE, ventilators, and some countermeasures.
•Detection baseline: Systems exist for influenza, respiratory viruses, and select zoonoses (though they failed early on COVID and have gaps on H5N1 spillover).
These are real. A 2020s novel pathogen would likely see faster countermeasure candidates than 2019.
Persistent and Worsened Weaknesses
•Supply chains and manufacturing: Heavy dependence on China and other foreign sources for APIs, antibiotics, PPE precursors, and reagents was exposed in 2020 and not fixed at scale. Domestic surge capacity remains limited; "reshoring" rhetoric has outpaced results. Just-in-time hospital inventories recur.
•Stockpiles and logistics: The SNS was understocked and poorly managed pre-COVID; replenishment has been incomplete and expiration-prone. Distribution botched last time (testing kits, early PPE). Ventilators and beds matter less than trained staff—nursing/respiratory therapist shortages and burnout predate and outlast COVID.
•Institutional credibility and decision-making: CDC, FDA, and NIH suffered major self-inflicted wounds: delayed testing, shifting guidance without evidence transparency (masks, aerosol vs. droplet, lab-leak dismissal), overreliance on flawed models, and suppression of dissenting views (Great Barrington). Public trust in these agencies cratered, especially after mandates, school closures, and downplaying natural immunity or myocarditis risks. Low trust slows uptake of any future countermeasure. Gain-of-function research and lab safety oversight remain contested and insufficiently transparent.
•Population vulnerability and healthcare system: High obesity, diabetes, and metabolic disease rates amplify severity for respiratory viruses (comorbidities drove the large majority of COVID deaths). Hospitals run near capacity in normal times; elective backlogs and workforce exit make surges costly. Excess non-COVID deaths and learning loss showed the price of broad NPIs.
•Governance and incentives: Emergency powers, liability shields, and funding flows incentivize overreaction and pharma alignment more than focused protection of the vulnerable or rapid randomized evidence. Political polarization turns every pathogen into a culture-war proxy. International dependence (WHO, supply) collides with sovereignty concerns. After-action reviews (GAO, bipartisan panels, Senate reports) repeatedly flag the same unfixed gaps.
Recent signals (H5N1 in cattle/dairy, scattered human cases) show surveillance works unevenly and risk communication is still clumsy. Preparedness indexes and simulations often grade the US highly on paper while real performance lags.
What "Prepared" Actually Requires
True readiness is not endless lockdowns or blank-check pharma contracts. It is: resilient domestic production of essentials; honest, rapid evidence generation (challenge trials, clean RCTs where ethical); transparent risk communication that distinguishes high-risk from low-risk groups; hospital and workforce surge without destroying the rest of medicine; and legal/policy frameworks that default to targeted measures rather than population-wide coercion. Innovation speed is a US advantage; turning every outbreak into a loyalty test or indefinite emergency is a liability.
Comparisons: The US outperforms many countries in countermeasure R&D and can outspend almost everyone. It underperformed peers on age-adjusted outcomes and collateral damage in COVID relative to its resources, partly from policy choices. No major country is "ready" for a high-fatality engineered or novel pathogen; most pretend otherwise.
COVID was a stress test that revealed brittle systems and overconfident experts. Incremental stockpile and platform gains help, but without fixing incentives, trust, manufacturing, and metabolic health, the next crisis will again feature shortages, confusion, and unnecessary harm. For primary sources, see GAO pandemic reports, SNS audits, CDC/NIH after-actions, and excess mortality analyses from 2020–2023.